Contact

Daniel Eisenkraft Klein, PhD, MSc

Our Team

Daniel Eisenkraft Klein, PhD, MSc

Postdoctoral Research Fellow

Daniel Eisenkraft Klein is a Postdoctoral Research Fellow with PORTAL and an Affiliate at the Harvard Medical School Center for Bioethics. His research focuses on pharmaceutical and health governance and ethics, with particular emphasis on how stakeholder input is solicited, structured, and weighted across regulatory and policy settings. His work also examines drug policy more broadly, including how medical, commercial, and criminal law systems converge in the regulation of substances such as opioids, nicotine, and psychedelics.

Klein’s work has been published in the American Journal of Public Health, The American Journal of Bioethics, Social Science & Medicine, JAMA Internal Medicine, and the Journal of Health Politics, Policy and Law, among others.

Klein previously served as a Policy Analyst for Health Canada. He received his undergraduate degree from McGill University and his MSc and PhD from the University of Toronto, where he was a Social Sciences and Humanities Research Council Doctoral Fellow.

Featured Work

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Glucagon-Like Peptide-1 Receptor Agonists and Pay-Per-Click Direct-To-Consumer Advertising

Eisenkraft Klein D, Zenone M, Kesselheim AS - JAMA Network Open

Research Publications

| October 2025

Price, Value, and Access
Regulation and Clinical Evidence

Over two years, $7.5 million was spent on pay-per-click (PPC) direct-to-consumer online advertising to promote semaglutide (Ozempic) in the US, with substantial spending targeting weight-loss keywords and competitor drug names, even though Ozempic is not FDA-approved for weight loss. Given that PPC advertising can influence consumer behavior, the FDA should issue guidelines on appropriate use of this advertising strategy or review PPC content to prevent misleading drug promotion.

View Source

Talk bubble graphics representing commentary and opinion.

The Case Against Six-Month Limits on Buprenorphine Telehealth Prescribing

Klein DE, Bullen M, Zhu DT, Kesselheim AS - Annals of Internal Medicine

Commentary & Opinion

| March 2026

Price, Value, and Access

The Drug Enforcement Agency’s (DEA) new rule requiring in-person visits after six months of telehealth-initiated buprenorphine treatment lacks clinical or public health justification and could disrupt care for patients with opioid use disorder. The authors contend that the rule’s seven exceptions are largely impractical for outpatient addiction settings and urge for the removal of the arbitrary time limit.

View Source